Evidence map›Paper›PMID 24936228›Full record

ArticleWorld journal of gastrointestinal oncology2014

Current status of pharmacological treatment of colorectal cancer.

Reyhan Akhtar, Shammy Chandel, Pooja Sarotra, Bikash Medhi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 47 citations in OpenAlex.

  1. The expression of ERAP1 is favorable for the prognosis and immunotherapy in colorectal cancer: a study based on the bioinformatic and immunohistochemical analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Colorectal cancer in young patients: is it a distinct clinical entity?International journal of clinical oncology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Reyhan AkhtarReyhan Akhtar, Shammy Chandel, Pooja Sarotra, Bikash Medhi, Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Shammy ChandelReyhan Akhtar, Shammy Chandel, Pooja Sarotra, Bikash Medhi, Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Pooja SarotraReyhan Akhtar, Shammy Chandel, Pooja Sarotra, Bikash Medhi, Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Bikash MedhiReyhan Akhtar, Shammy Chandel, Pooja Sarotra, Bikash Medhi, Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo review the clinical trials for the development in drugs for chemotherapeutic treatment of colorectal cancer (CRC).

methodsA systematic review identified randomized controlled trials (RCTs) assessing drugs for the treatment of CRC or adenomatous polyps from www.clinicaltrials.gov. Various online medical databases were searched for relevant publications.

resultsCombination treatment regimens of standard drugs with newer agents have been shown to improve overall survival, disease-free survival, time to progression and quality of life compared to that with standard drugs alone in patients with advanced colorectal cancer. The FOLFOXIRI regimen has been associated with a significantly higher response rate, progression-free survival and overall survival compared to the FOLFIRI regimen.

conclusionOxaliplatin plus intravenous bolus fluorouracil and leucovorin has been shown to be superior for disease-free survival when compared to intravenous bolus fluorouracil and leucovorin. In addition, oxaliplatin regimens were more likely to result in successful surgical resections. First line treatment with cetuximab plus fluorouracil, leucovorin and irinotecan has been found to reduce the risk of metastatic progression in patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases. The addition of bevacizumab has been shown to significantly increase overall and progression-free survival when given in combination with standard therapy.

Indexed as

5-fluorouracilChemotherapyColorectal cancerEpidermal growth factor receptor inhibitorLeucovorinMetastasis

Identifiers

PMID24936228
PMCPMC4058725
OpenAlexW1586425132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.